Navigation Links
Bunge Reports Fourth Quarter Net Income of $245 Million
Date:2/7/2008

COME

(In millions, except per share data and percentages)

(Unaudited)

Quarter Ended Year Ended

December 31, Percent December 31, Percent

2007 2006 Change 2007 2006 Change

Net sales $14,018 $7,683 82% $44,804 $26,274 71%

Cost of goods

sold (13,242) (7,169) 85% (42,289) (24,703) 71%

Gross profit 776 514 51% 2,515 1,571 60%

Selling, general

and administrative

expenses (434) (278) 56% (1,359) (978) 39%

Interest income 54 32 69% 166 119 39%

Interest expense (73) (68) (7)% (217) (195) 11%

Interest expense on

readily marketable

inventories (29) (18) 61% (136) (85) 60%

Foreign exchange

gain (loss) 39 24 217 59

Other income

(expense) - net 17 24 (29)% 15 31 (52)%

Income from

operations before

income tax 350 230 52% 1,201 522 130%

Income tax

(expense)

benefit (89) 69 (310) 36

Income from

operations after

income tax 261 299 (13)% 891 558 60%

Minority interest (42) (22) 91% (146) (60) 143%

Equity in earnings

of affiliates 26 (13) 300% 33 23 43%

Net income 245 264 (7)% 778 521 49%

Convertible

preference

share dividends (15) (4) (40) (4)

Net income

available

to common

sha
'/>"/>

SOURCE Bunge Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Recent Research Reports and Near-Term Corporate Events
5. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
6. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
7. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
8. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
9. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
10. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
11. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 2La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4